Company profile
CaliPharms, Inc.
OTC: KGET · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Temecula, CIK 0001082176Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 33
v0.1 · 5/100 weight · pillars only
↑ listing tenure, Piotroski F · ↓ Altman-Z, return on assets
Methodology →Revenue TTM
$112.5k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$302.9k
Employees
4
as of 2026-08-27
Market cap
$474.3k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$302.9k-$302.9k2013
Operating income-$273.6k-$273.6k2013
Total assets$21.4k$21.4k2013
Liabilities$335.3k$335.3k2013
Equity-$313.8k-$313.8k2013
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CaliPharms, Inc.’s financial profile?
CaliPharms, Inc. earned -$302.9k in FY2013 net income.
Peers · Healthcare
Nascent Pharma Holdings, Inc.——Stella Diagnostics Inc.——Solanbridge Group, Inc.——Canopus Biopharma, Inc.——OJsys, Inc.——PPJ Healthcare Enterprises, Inc.——Key facts
CEOEric Watson
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersTemecula, null
ExchangeOTC: KGET
Employees4
IPO date2013-12-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.